Viridian Therapeutics to Participate in Upcoming June Investor Conferences May 27, 2026 View Press Release
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million May 6, 2026 View Press Release
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock May 5, 2026 View Press Release
